Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer (MPV-CICU)
15. juni 2026 oppdatert av: Eda Cennet Caferoğlu, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU).
Patients with cancer are highly vulnerable to complications and organ failure, making early risk assessment vital for improving treatment strategies.
Researchers will retrospectively review the medical charts and electronic health records of adult patients who stayed in the anesthesia ICU for longer than 24 hours between 2020 and 2025.
No new laboratory tests, interventions, or patient contact will occur.
The collected data will be analyzed to determine the relationship between initial MPV levels and patient survival outcomes.
Studieoversikt
Status
Påmelding etter invitasjon
Forhold
Detaljert beskrivelse
This retrospective, observational, single-center study will evaluate the predictive value of initial Mean Platelet Volume (MPV) and other hemogram parameters (such as Red Cell Distribution Width [RDW] and platelet count) on intensive care and hospital mortality. The primary objective is to investigate the correlation between these routinely measured, cost-effective biomarkers and survival outcomes in oncological critical care patients. The study hypotheses are structured as follows:
- H0: There is no significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer.
- H1: There is a significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer. Data regarding demographics (age, sex), clinical diagnoses, comorbidities, length of stay, APACHE II, SOFA scores, and laboratory parameters (CRP, procalcitonin) will be extracted from hospital electronic database records. All patient data will be anonymized before statistical analysis.
Note on Study Design: This study is designed as a retrospective cohort study. Due to system registry constraints in the protocol module, the time perspective has been specified as 'Other' (Retrospective Cohort).
Studietype
Observasjonsmessig
Registrering (Antatt)
425
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Ankara, Tyrkia (Türkiye)
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
The study population consists of adult oncological patients who required critical care and were admitted to the anesthesia intensive care unit of a tertiary oncology training and research hospital between 2020 and 2025.
Beskrivelse
Inclusion Criteria:
- Adult patients aged 18 years and older.
- Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
- Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
- Patients with an ICU length of stay longer than 24 hours.
- Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.
Exclusion Criteria:
- Patients under the age of 18.
- Patients who stayed in the intensive care unit for less than 24 hours.
- Patients with missing or incomplete medical charts, laboratory data, or survival status records.
- Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
- Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Oncological ICU Patients
Adult patients (aged 18 and older) with a confirmed cancer diagnosis who were admitted to the anesthesia intensive care unit for longer than 24 hours between the years 2020 and 2025
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intensive Care Unit (ICU) Mortality
Tidsramme: From the date of ICU admission up to ICU discharge, assessed up to 30 days.
|
The percentage of oncological patients who died during their stay in the anesthesia intensive care unit.
This will be calculated based on the electronic health records and patient files.
|
From the date of ICU admission up to ICU discharge, assessed up to 30 days.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hospital Mortality
Tidsramme: From the date of hospital admission up to hospital discharge, assessed up to 60 days.
|
The percentage of oncological patients who died during their overall hospital stay (including post-ICU ward follow-up).
|
From the date of hospital admission up to hospital discharge, assessed up to 60 days.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
15. juni 2026
Primær fullføring (Antatt)
1. august 2026
Studiet fullført (Antatt)
1. august 2026
Datoer for studieregistrering
Først innsendt
15. juni 2026
Først innsendt som oppfylte QC-kriteriene
15. juni 2026
Først lagt ut (Faktiske)
18. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-05/106
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
Individual participant data will not be shared globally to maintain patient confidentiality and privacy in accordance with local data protection regulations and institutional review board restrictions.
However, the coded datasets and statistical analyses used during the current study may be available from the corresponding author upon reasonable academic request.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .